A Study on Borna Disease Virus Infection in Domestic Cats in Japan

Azusa SOMEYA1), Ryoko FUKUSHIMA2), Michiko YOSHIDA2), Yasuyuki TANAHASHI1), Tangmunkhong PRAPEUK2,3), Reiko IIZUKA4), Hiroshi HIRAMI4), Atsushi MATSUDA5), Shunichi TAKAHASHI6), Goro KURITA7), Takashi KIMURA8,10), Misuzu SEO1), Masayuki FUNABA9) and Yoshii NISHINO1,2)*

1)Department of Animal Medical Sciences, Faculty of Life Sciences, Kyoto Sangyo University, Motoyama, Kamigamo, Kita-ku, Kyoto 603–8555, Japan
2)Research Institute of Biosciences, Azabu University, 1–17–71 Fuchinobe, Chuo-ku, Sagamihara 252–5201, Japan
3)Department of Veterinary Public Health, Faculty of Veterinary Medicine, Kasetsart University, Nakornpathom 73140, Thailand
4)Hirami Animal Hospital, Tateno-cho, Nerima-Ku, Tokyo 177–0054, Japan
5)Hoshigaoka Animal Hospital, 4–4–5 Hoshigaoka, Chuo-ku, Sagamihara 252–0238, Japan
6)FAH Takahashi Animal Hospital, 1785–1 Shimotsuruma, Yamato 242–0001, Japan
7)Kurita Animal Hospital, 139–1 Furukawa, Furukawa 306–0016, Japan
8)Laboratory of Comparative Pathology, Department of Veterinary Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Kita-18, Nishi-9, Sapporo 060–0818, Japan
9)Division of Applied Biosciences, Kyoto University Graduate School of Agriculture, Kitashirakawa Oiwakecho, Kyoto 606–8502, Japan
10)Present address: Division of Molecular Pathobiology, Research Center for Zoonosis Control, Hokkaido University, Kita-20, Nishi-10, Sapporo 001–0020, Japan

(Received 7 July 2013/Accepted 18 April 2014/Published online in J-STAGE 8 May 2014)

ABSTRACT. Borna disease virus (BDV) infection causes neurological disease in cats. Here, we report BDV infection in 199 hospitalized domestic cats in the Tokyo area. BDV infection was evaluated by detection of plasma antibodies against BDV-p24 or -p40. BDV-specific antibodies were detected in 54 cats (27.1%). Interestingly, the percentage of seropositive cats was not significantly different among the three clinical groups, i.e., healthy (29.8%), neurologically asymptomatic disease (22.2%) and neurological disease (33.3%). The specific antibodies were detected in 54 cats (27.1%). Interestingly, the percentage of seropositive cats was not significantly different among the three clinical groups, i.e., healthy (29.8%), neurologically asymptomatic disease (22.2%) and neurological disease (33.3%). The specific antibodies were detected in 54 cats (27.1%). Interestingly, the percentage of seropositive cats was not significantly different among the three clinical groups, i.e., healthy (29.8%), neurologically asymptomatic disease (22.2%) and neurological disease (33.3%).

NOTE. Virology

Borna disease virus (BDV), a nonsegmented, enveloped, negative-strand RNA virus of the Bornavirus family [8], is the causative agent of Borna disease, an often fatal meningoencephalitis originally described in horses and sheep in Germany. Thereafter, natural BDV infection has been reported in many warm-blooded animals [15]. BDVPersistently infects the central nervous system and often induces encephalitis [15]; experimental BDV infection has been shown to induce severe neurological disorders characterized by behavioral abnormality and movement disorders in laboratory rodents [15]. The domestic cat, Felis catus, is one of the natural hosts of BDV [8]. BDV causes staggering disease in cats, characterized by behavioral and motor disturbances with ataxia, behavioral change and loss of postural reaction [9–11]. Experimental BDV infection caused behavioral and motor disturbances with encephalitis in 4 cats among 7 infected cats [11]. This indicates that persistent BDV infection is related to, but not sufficient for onset of staggering disease in cats. Consistent with these results, our previous study of 32 clinically healthy domestic cats living in the Tokyo area of Japan revealed more than 20% of the cats were infected with BDV [13]; however, the sample size of the previous study was relatively small. The present study further investigated BDV infection in healthy cats. In addition, BDV infection in cats with neurologically asymptomatic disease and those with neurological disease was also evaluated.

A total of 199 domestic cats living in the Tokyo area were examined for the present study. They were hospitalized at the Veterinary Teaching Hospital of Azabu University or four private animal hospitals between September 1996 and April 1999. The cats were categorized by veterinarians into 3 groups: clinically healthy (healthy: 94 cats), neurologically asymptomatic disease (NA: 81 cats) or neurological disease (ND: 24 cats). In addition, sampling date was categorized into 4 seasons on the basis of monthly average temperature in Tokyo as follows: spring – March, April and May (average temperature 8.5, 14.1 and 18.6°C, respectively); summer – June, July, August and September (21.7, 25.2, 27.1 and 23.2°C, respectively); fall – October and November (17.6 and 12.6°C, respectively); and winter – December, January and February (7.9, 5.2 and 5.6°C, respectively). Owners

©2014 The Japanese Society of Veterinary Science
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License <http://creativecommons.org/licenses/by-nc-nd/3.0/>.
were briefly on the purpose of the study, and their consent was obtained. Blood samples (4 ml) collected in EDTA-coated tubes were immediately chilled at 4°C, and plasma was collected within 24 hr.

Expression and purification of glutathione-S-transferase (GST), GST-fused BDV p24 and GST-fused p40 were conducted as described previously [12]. Briefly, GST alone or GST-fused protein expressed in E. coli BL21 was purified near homogeneity by use of glutathione-Sepharose (GE Healthcare UK, Little Chalfont, Buckinghamshire, U.K.) and subsequent electroelution of recovered appropriate band after preparative SDS-PAGE. Detection of anti-BDV antibody was conducted by Western blot analyses. Nineteen pmol of GST, GST-BDV-p24 and GST-BDV-p40 were subjected to 12.5% SDS-PAGE and transferred to the PVDF membranes (Merck Millipore, Billerica, MA, U.S.A.). The membranes were blocked with skim milk (Block Ace, Dainippon Sumitomo Pharmaceuticals, Osaka, Japan) for 16 hr at 4°C. The membranes were then incubated with plasma, which was preadsorbed with GST and diluted with PBS containing 0.05% (v/v) Tween-20 (PBS-T) at 1:200 for 16 hr at 4°C. After washing with PBS-T for 40 min at 25°C, the membranes were reacted with peroxidase-conjugated anti-cat IgG antibody (Nordic-MUBio, Susteren, Netherlands) diluted at 1:6,000 with PBS containing 0.05% (v/v) Tween-20 (PBS-T) at 1:200 for 16 hr at 4°C. The membranes were then incubated with plasma, which was preadsorbed with GST and diluted with PBS containing 0.05% (v/v) Tween-20 (PBS-T) at 1:200 for 16 hr at 4°C. After washing with PBS-T for 40 min at 25°C, the membranes were reacted with peroxidase-conjugated anti-cat IgG antibody (Nordic-MUBio, Susteren, Netherlands) diluted at 1:6,000 with PBS-T for 40 min at 25°C. After washing with PBS-T for 40 min at 25°C, the immunoreactive molecules were visualized by use of ECL reagent (ECL detection kit, GE Healthcare UK).

When a significant band at GST-BDV p24 or p40 was detected, Western blot analyses were conducted again using the plasmas adsorbed with GST-BDV p24 or GST-BDV p40 beads, respectively. The cat plasma was judged to be seropositive if it reacted with GST-BDV proteins but not GST alone, and immunoreactions were reduced against GST-BDV proteins by adsorption with the respective protein beads (data not shown); cats with either anti-BDV p24 or p40 antibody were judged as those infected with BDV or BDV-related viruses. Infection with feline immunodeficiency virus (FIV) was also evaluated by the presence of anti-FIV antibody in plasma using a commercial kit (SNAP FcLV/FIV Combo, IDEXX Laboratories, Westbrook, ME, U.S.A.). Data were analyzed by χ² test to compare groups. Statistical significance was set at P<0.05.

BDV infection of domestic cats in the Tokyo area is shown in Table 1. A total of 54 cats among 199 cats (27.1%) were infected with BDV, and the percentage of BDV infection was not significantly different among the three groups: healthy (28/94, 29.8%), NA (18/81, 22.2%) and ND (8/24, 33.3%). Analyses on the relationship to clinical condition indicated a significantly higher BDV prevalence in cats suffering from stomatopathy (9/13, 69.2%) than in the healthy group (P<0.05) and in the ND group (P<0.05). Percentage of positive for anti-BDV p24 antibody was similar to that for anti-BDV p40 antibody in the healthy group and NA group. On the other hand, there tended to be more cats with anti-BDV p24 antibody than those with anti-BDV p40 antibody in the ND group.

Risk factors affecting BDV prevalence were next analyzed in domestic cats in the Tokyo area of Japan. Gender of cats did not affect BDV prevalence (data not shown). To examine the effect of age, cats were categorized into 4 groups: younger than one year (<1 yr), 1 to 4 years old (1–4 yr), 5 to 8 years old (5–8 yr) and 9 years old or older (>9 yr) (Table 2). Interestingly, the specific antibodies were present even in cats aged below one year (13/49, 26.5%), and the seroprevalence against BDV was relatively constant, irrespective of the age. The sampling season did not affect the seroprevalence against BDV, although it was slightly lower in fall than in the other seasons (Table 2).

The present study found that more than one-fourth of 199 cats in the Tokyo area of Japan are suspected to have been infected with BDV. Consistent with our previous study [13] and another study [4, 12, 14], a significant population of cats was infected with BDV without manifesting any clinical abnormalities. Even experimental BDV infection by intracranial injection did not cause Borna disease in 3 of 7 infected cats [11]. Therefore, it is thought that additional risk factor(s) is necessary for the onset of Borna disease in addition to BDV infection in naturally infected cats.

A previous study showed that higher BDV prevalence, which was judged by the presence of anti-BDV antibody, was detected in FIV-positive cats than in FIV-negative cats [3]; risk factors for FIV infection, such as fighting and biting, may overlap with those for BDV transmission in cats [3]. Multiple infections are possibly involved in the onset of neurological disorders in BDV-infected cats. Thus, we evaluated FIV infection. As a result, 2 cats among 8 BDV-infected cats were positive for FIV in the ND group, whereas no cat was positive for FIV among 18 BDV-infected cats in the NA group (data not shown). Clearly, further studies are needed because of the limited sample numbers, but FIV infection may trigger the induction of neurological diseases in BDV-infected cats [6].

A higher prevalence of BDV infection was detected in cats suffering from stomatopathy. Currently, the reason is unknown, and future experimental studies are needed to clarify the relationship between higher seropositive rate and stomatopathy; reactivation of persistent BDV infection as well as onset of stomatopathy may occur due to a reduction in the body's tolerance.

Currently, the transmission route of BDV is unclear in cats. There are 2 possibilities: horizontal transmission and vertical transmission. As for horizontal transmission of BDV in cats, reports have suggested that wild rodents transmit BDV to cats in Sweden and Finland [1, 7]. Insects are also candidates for transmitting BDV to cats. However, in Japan, BDV infection was not detected in wild rodents [16]. In addition, the present study found no effect of sampling season on BDV prevalence; if insects mediate BDV infection in cats, seroprevalence against BDV in cats would be affected by the sampling season because of the seasonal variation in the activity of insects. Thus, we think that horizontal transmission is not a major route in BDV infection in Japan. A previous study [14] that the age of cats had no effect on the seroprevalence against BDV supports this conclusion; the BDV seropositive population, which is persistently infected,
BDV INFECTION IN CATS

Table 1. Prevalence of anti-BDV antibodies in domestic cats in relation to their clinical condition

| Clinical condition                        | Total subjects | Anti-BDV antibodies (%)a) |
|------------------------------------------|----------------|---------------------------|
|                                          |                | Total | p24 | p40 | p24+p40 |
| Healthy                                  | 94             | 28 (29.8) | 20 | 22 | 14 |
| Neurologically asymptomatic disease (NA) | 81             | 18 (22.2) | 14 | 13 | 9  |
| LUTDb)                                   | 15             | 4 (26.7) | 4  | 3  | 3  |
| Tumorc)                                  | 18             | 1 (5.6) | 1  | 0  | 0  |
| Splanchnopathyd)                         | 15             | 6 (40.0) | 5  | 3  | 2  |
| Infectious diseasc)                      | 14             | 3 (21.4) | 2  | 2  | 1  |
| Stomatopathye)                           | 13             | 9 (69.2) *†| 7  | 5  | 3  |
| Traumag)                                 | 7              | 1 (14.3) | 0  | 1  | 0  |
| Othersh)                                 | 10             | 1 (10.0) | 1  | 0  | 0  |
| Neurological disease (ND)                | 24             | 8 (33.3) | 7  | 3  | 2  |
| Total                                    | 199            | 54 (27.1) | 41 | 38 | 25 |

a) Figure within parenthesis indicates the percentage of positive to the total number within the same line. b) Lower urinary tract disease. Includes 2 cats with supervening infectious disease and 2 cats with supervening tumor or trauma. c) Includes 4 cats, 1 of each with supervening LUTD, stomatopathy, splanchnopathy or infectious disease. d) Includes 2 cats with supervening stomatopathy and 1 cat with supervening trauma. e) Viral infection and suppurative bacterial infection. Includes 4 cats, 1 of each with supervening LUTD, stomatopathy, splanchnopathy or trauma. f) Includes 3 cats with supervening splanchnopathy and 2 cats with supervening tumor or infectious disease. g) Including 2 cats, 1 of each with supervening LUTD or infectious disease. h) Dehydration, emaciation, depression, mixed connective tissue disease and dermatitis. *: P<0.05 as compared with the healthy group. †: P<0.05 as compared with the ND group.

Table 2. Effects of age and sampling season on BDV infection in cats

| Cat’s ageb) | Total Subjectsa) | Positive for BDV (%)a) |
|-------------|------------------|------------------------|
| <1 yr       | 49               | 13 (26.5)              |
| 1–4 yr      | 60               | 15 (25.0)              |
| 5–8 yr      | 31               | 10 (32.3)              |
| >9 yr       | 36               | 10 (27.8)              |
| Sampling seasonc) |  |  |
| Spring      | 53               | 17 (32.1)              |
| Summer      | 41               | 12 (29.3)              |
| Fall        | 33               | 5 (15.2)               |
| Winter      | 70               | 19 (27.1)              |

a) Figure within parenthesis indicates the percentage of positive to the total number within the same line. b) Samples from 176 cats were analyzed. c) Samples from 197 cats were analyzed.

ACKNOWLEDGMENTS. We thank Dr. K. Ikuta (Osaka University, Osaka, Japan) for the kind gift of anti-BDV antibodies and expression plasmids of BDV-p24 and -p40 proteins, Dr. R. Rott (Justus-Liebig-Universitat Giessen, Giessen, Germany) for providing MDCK/BDV cells and Drs. M. Tadokoro, Y. Fujita and T. Hakata for technical support. This work was partly supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan.

REFERENCES

1. Berg, A. L., Reid-Smith, R., Larsson, M. and Bonnett, B. 1998. Case control study of feline Borna disease in Sweden. Vet. Rec. 142: 715–717. [Medline] [CrossRef]
2. Hagiwara, K., Kamitani, W., Takamura, S., Taniyama, H., Nakaya, T., Tanaka, H., Kirisawa, R., Iwai, H. and Ikuta, K. 2000. Detection of Borna disease virus in a pregnant mare and her fetus. Vet. Microbiol. 72: 207–216. [Medline] [CrossRef]
3. Helps, C. R., Turan, N., Bilal, T., Harbour, D. A. and Yilmaz, H. 2001. Detection of antibodies to Borna disease virus in Turkish cats by using recombinant p40. Vet. Rec. 149: 647–650. [Medline] [CrossRef]
4. Horii, Y., Garcia, N. P., Noviana, D., Kono, F., Sawada, T., Naraiki, T. and Yamaguchi, K. 2001. Detection of anti-borna disease virus antibodies from cats in Asian countries, Japan, Philippines and Indonesia using electrochemiluminescence immunoassay. J. Vet. Med. Sci. 63: 921–923. [Medline] [CrossRef]
5. Johnson, R. P. and Povey, R. C. 1983. Transfer and decline of maternal antibody to feline calicivirus. Can. Vet. J. 24: 6–9. [Medline]
6. Kamibieh, S., Hodgson, J. L., Bode, L., Ludwig, H. and Flower, R. L. 2008. Borna disease virus: evidence of naturally-occurring infection in cats in Australia. APMS Suppl. 116: 50–52. [Medline] [CrossRef]
7. Kinnunen, P. M., Billich, C., Ek-Kommonen, C., Hentononen, H., Kallio, R. K., Niemimaa, J., Palva, A., Staeheli, P., Vaheeri, A.
and Vapalahti, O. 2007. Serological evidence for Borna disease virus infection in humans, wild rodents and other vertebrates in Finland. *J. Clin. Virol.* **38**: 64–69. [Medline] [CrossRef]

8. Kishi, M., Tomonaga, T., Lai, P. and de la Torre, J.C. 2002. Borna disease virus molecular virology, pp. 23–43. In: *Borna Disease Virus and Its Role in Neurobehavioral Disease* (Carbone, K.M. ed.), ASM Press, Washington, D.C.

9. Kronevi, T., Nordstrom, M., Moreno, W. and Nilsson, P. O. 1974. Feline ataxia due to nonsuppurative meningoencephalomyelitis of unknown aetiology. *Nord. Vet. Med.* **26**: 720–725. [Medline]

10. Lundgren, A. L. 1992. Feline non-suppurative meningeencephalomyelitis: a clinical and pathological study. *J. Comp. Pathol.* **107**: 411–425. [Medline] [CrossRef]

11. Lundgren, A. L., Zimmermann, W., Bode, L., Czech, G., Gossztonyi, G., Lindberg, R. and Ludwig, H. 1995. Staggering disease in cats: isolation and characterization of the feline Borna disease virus. *J. Gen. Virol.* **76**: 2215–2222. [Medline] [CrossRef]

12. Nakamura, Y., Asahi, S., Nakaya, T., Bahmani, M. K., Saitoh, S., Yasui, K., Mayama, H., Hagiwara, K., Ishihara, C. and Ikuta, K. 1996. Demonstration of Borna disease virus RNA in peripheral blood mononuclear cells derived from domestic cats in Japan. *J. Clin. Microbiol.* **34**: 188–191. [Medline]

13. Nishino, Y., Funaba, M., Fukushima, R., Mizutani, T., Kimura, T., Iizuka, R., Hirami, H. and Harai, M. 1999. Borna disease virus infection in domestic cats: evaluation by RNA and antibody detection. *J. Vet. Med. Sci.* **61**: 1167–1170. [Medline] [CrossRef]

14. Ouchi, A., Kishi, M., Kobayashi, T., Lai, P. K., Malik, T. H., Ikuta, K. and Mochizuki, M. 2001. Prevalence of circulating antibodies to p10, a non-structural protein of the Borna disease virus in cats with ataxia. *J. Vet. Med. Sci.* **63**: 1279–1285. [Medline] [CrossRef]

15. Rott, R. and Becht, H. 1995. Natural and experimental Borna disease in animals. pp. 17–30. In: *Borna Disease* (Koprowski, H. and Lipkin, W.I. eds.), Springer Verlag KG, Berlin.

16. Tsujimura, K., Mizutani, T., Kariwa, H., Yoshimatsu, K., Ogino, M., Morii, Y., Inagaki, H., Arikiwa, J. and Takashima, I. 1999. A serosurvey of Borna disease virus infection in wild rats by a capture ELISA. *J. Vet. Med. Sci.* **61**: 113–117. [Medline] [CrossRef]